T. Rowe Price Associates
ELVN icon

T. Rowe Price Associates’s Enliven Therapeutics ELVN Stock Holding History

T. Rowe Price Associates’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.83M Buy
97,747
+73,947
+311% +$2.05M ﹤0.01% 1530
2025
Q4 		$367K Sell
23,800
-207,504
-90% -$4.13M ﹤0.01% 2538
2025
Q3 		$4.74M Sell
231,304
-296,946
-56% -$5.99M ﹤0.01% 1409
2025
Q2 		$10.6M Buy
528,250
+512,090
+3,169% +$9.69M ﹤0.01% 1101
2025
Q1 		$319K Buy
16,160
+2,533
+19% +$54.5K ﹤0.01% 2440
2024
Q4 		$307K Buy
13,627
+1,980
+17% +$51.3K ﹤0.01% 2499
2024
Q3 		$298K Buy
11,647
+440
+4% +$10.2K ﹤0.01% 2480
2024
Q2 		$262K Buy
+11,207
New +$236K ﹤0.01% 2485

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's ELVN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Enliven Therapeutics (ELVN) stake by 311% in Q1 2026, buying an estimated $2.05M and bringing the position to 97,747 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1530.

T. Rowe Price Associates first reported a position in ELVN in Q2 2024 and has held it in 8 quarters since. The position peaked at $10.6M in Q2 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • T. Rowe Price Associates held 97,747 shares of Enliven Therapeutics worth $3.83M as of Q1 2026.
  • T. Rowe Price Associates bought 73,947 Enliven Therapeutics shares in Q1 2026, an estimated $2.05M.
  • Enliven Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1530 holding.
  • T. Rowe Price Associates first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • T. Rowe Price Associates's Enliven Therapeutics position peaked at $10.6M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.